16 September 2026 editorial review · Item
Insulin lispro (Humalog): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: Insulin lispro (Humalog)
Scope and findings:
- Read label PK/PD:30–90min serum peak,variable person/site/activity response and more rapid onset/shorter duration than regular insulin. The cited DailyMed label is historical; current regional availability and price claims not established by it.
Primary sources checked:
Limits: The review is restricted to the scopes above. Historical efficacy estimates, editorial scoring and country-specific access were not fully reverified unless expressly stated. A manufacturer or conference report retains that evidence level.